EZH2 and follicular lymphoma: The inhibition of EZH2 with tazemetostat has been studied in a phase 2 clinical trial in patients with relapsed/refractory follicular lymphoma; this study showed an 69% objective response rate in the EZH2-mutated cohort [140].